查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
患者衍生異種移植 (PDX) 模型市場，按腫瘤類型、模型、最終用戶、國家和地區分類 - 2023-2030 年行業分析、市場規模、市場佔有率和預測
市場調查報告書
商品編碼
1351394

患者衍生異種移植 (PDX) 模型市場，按腫瘤類型、模型、最終用戶、國家和地區分類 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Patient Derived Xenograft (PDX) Model Market, By Tumor Type, By Model, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 246 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022 年病患衍生異種移植 (PDX) 模型市場規模為 2.906 億美元，2023 年至 2030 年年複合成長率為 13.2%。

病患衍生異種移植 (PDX) 模型市場 - 市場動態：

  • 全球癌症盛行率的不斷上升推動了市場的成長
  • 全球癌症盛行率的不斷上升預計將在預測期內推動市場成長。例如，根據美國國家癌症研究所發布的報告，截至2022年1月，美國將有1,810萬癌症倖存者，相當於總人口的5.4%左右。在美國，有 623,405 人患有轉移性乳癌、攝護腺癌、肺癌、大腸癌、膀胱癌或黑色素瘤，到 2025 年，這一數位預計將增至 693,452 人。此外，根據英國癌症研究中心的數據，如果發病率保持穩定並且人口成長和老化繼續以目前的速度進行，預計到 2040 年，全球每年將新增 2800 萬癌症病例。比 2020 年成長 54.9%，預計男性（成長 60.6%）高於女性（成長 48.8%）。因此，上述事實推動了預測期內的市場成長。

患者衍生異種移植 (PDX) 模型市場 - 主要見解：

  • 根據我們的研究分析師分享的分析，全球患者衍生異種移植 (PDX) 模型市場預計在預測期內（2023-2030 年）每年將以 13.2% 左右的年複合成長率成長
  • 由於癌症盛行率不斷上升，患者衍生異種移植（PDX）模型產業預計將大幅成長。
  • 根據腫瘤類型，預計乳癌細分市場將在預測期內主導市場。
  • 從地區來看，預計北美將在預測期內主導市場。

患者衍生異種移植 (PDX) 模型市場細分分析：

  • 全球患者衍生異種移植（PDX）模型市場根據腫瘤類型、模型、最終用戶和區域進行細分。
  • 根據腫瘤類型，全球患者衍生異種移植（PDX）模型市場分為攝護腺癌、胰臟癌、肺癌、乳癌等。預計乳癌細分市場將在預測期內主導市場。儘管隨著時間的推移，檢測和治療方法取得了重大進步，但乳癌仍然是全世界女性死亡的主要原因。使用目前的藥物，消滅腫瘤具有挑戰性，因為它們由極其多樣化的群體組成，包括乳癌。由於乳癌的腫瘤間異質性，使用常用的癌症模型（例如體外和體內創建的細胞系）也很難準確預測治療效果。因此，PDX 模型的創建是為了更真實地描述人類惡性腫瘤起源的變異性。這些模型可望改善乳癌治療方式。從而推動預測期內的細分市場成長。

患者衍生異種移植 (PDX) 模型市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。這些區域根據開展業務的國家進一步分類。由於癌症盛行率不斷上升，預計北美將在預測期內主導市場。此外，不斷增加的研發投入也是推動產業擴張的重要因素。此外，該地區主要參與者的存在預計將推動市場成長。例如，2023 年 4 月，在 2023 年美國癌症研究協會 (AACR) 年會上，生物製藥公司 Vincerx Pharma, Inc. 展示了一張海報： VIP236 單藥療法在不同腫瘤類型的PDX 和轉移性PDX 小鼠模型中的臨床前數據。因此，此類舉措預計將推動該地區的市場成長。

病患衍生異種移植（PDX）模型市場-競爭格局：

市場的主要參與者包括： WuXi AppTec、XenTech、Crown Bioscience、Altogen Labs、Envigo、Charles River Laboratories、Oncodesign、Hera Biolabs、The Jackson Laboratory 和 Abnova Corp。

最近的發展：

2022年7月，GemPharmatech（GemPharmatech Co., Ltd.）宣布與Charles River Laboratories, Inc.簽訂策略授權協議，獨家經銷其新一代NOD CRISPR Prkdc Il2r gamma（NCG）小鼠品系北美。該協議的目標是加快開發新療法，以滿足各種未滿足的醫療需求，特別是免疫腫瘤學領域。為了生產將於 2023 年開始銷售的模型，Charles River 將創建基礎殖民地。

目錄

第 1 章：病患衍生異種移植 (PDX) 模型市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按腫瘤類型分類的患者衍生異種移植 (PDX) 模型市場片段
    • 患者衍生異種移植 (PDX) 模型市場片段（按模型）
    • 最終用戶的患者衍生異種移植 (PDX) 模型市場片段
    • 按國家/地區分類的患者衍生異種移植 (PDX) 模型市場片段
    • 按地區分類的患者衍生異種移植 (PDX) 模型市場片段
  • 競爭洞察

第 3 章：患者衍生異種移植 (PDX) 模型主要市場趨勢

  • 患者衍生異種移植 (PDX) 模型市場促進因素
    • 市場促進因素的影響分析
  • 病患衍生異種移植（PDX）模型市場限制
    • 市場限制影響分析
  • 患者衍生異種移植 (PDX) 模型的市場機會
  • 病患衍生異種移植（PDX）模型市場未來趨勢

第 4 章：病患來源異種移植 (PDX) 模型產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：病患衍生異種移植 (PDX) 模型市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長部分
    • 最鬆散的部分
    • 邊際損失部分

第 6 章：病患衍生異種移植 (PDX) 模型市場格局

  • 2022 年病患衍生異種移植 (PDX) 模型市佔率分析
  • 按主要製造商分類的故障數據
    • 既定玩家分析
    • 新興玩家分析

第 7 章：患者衍生異種移植 (PDX) 模型市場 - 按腫瘤類型

  • 概述
    • 按腫瘤類型分類的細分市場佔有率分析
    • 攝護腺癌
    • 胰腺癌
    • 肺癌
    • 乳癌
    • 其他

第 8 章：病患衍生異種移植 (PDX) 模型市場 - 按模型

  • 概述
    • 按型號分類的細分市場佔有率分析
    • 老鼠
    • 老鼠

第 9 章：患者衍生異種移植 (PDX) 模型市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 製藥和生物製藥公司
    • 學術及研究機構
    • CRO 和 CDMO

第 10 章：病患衍生異種移植 (PDX) 模型市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美患者源性異種移植 (PDX) 模型主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按腫瘤類型）
    • 北美市場規模和預測（按型號）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲患者源性異種移植 (PDX) 模型主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按腫瘤類型）
    • 歐洲市場規模與預測（按模型）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區患者源性異種移植 (PDX) 模型主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（依腫瘤類型）
    • 亞太地區市場規模與預測（按模型）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲患者源性異種移植 (PDX) 模型主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按腫瘤類型）
    • 拉丁美洲市場規模和預測（按模式）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲患者源性異種移植 (PDX) 模型主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按腫瘤類型）
    • 中東和非洲市場規模及預測（按模式）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 病患衍生異種移植 (PDX) 模型產業

  • 競爭儀表板
  • 公司簡介
    • WuXi AppTec
    • XenTech
    • Crown Bioscience
    • Altogen Labs
    • Envigo
    • Charles River Laboratories
    • Oncodesign
    • Hera Biolabs
    • The Jackson Laboratory
    • Abnova Corp.

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV1643

REPORT HIGHLIGHT

Patient Derived Xenograft (PDX) Model Market size was valued at USD 290.6 Million in 2022, expanding at a CAGR of 13.2% from 2023 to 2030.

Patient-derived xenografts (PDX) are cancer models in which a patient's tumor tissue or cells are implanted into immunocompromised or humanized mice. This procedure involves xenotransplantation. To maintain the development of cancer after it has been removed from a patient, PDX models are employed. This allows for the monitoring of tumor development in the lab, including how it responds to various therapy choices. A PDX model from a given patient can be evaluated against a variety of medicines in a 'personalized oncology' approach, or cohorts of PDX models can be used to assess the therapeutic effectiveness of a drug against distinct forms of cancer.

Patient Derived Xenograft (PDX) Model Market - Market Dynamics:

  • The growing prevalence of cancer across the globe drives the market growth
  • The growing prevalence of cancer across the globe is expected to drive market growth during the forecast period. For instance, according to the report published by National Cancer Institutes, there would be 18.1 million cancer survivors in the US as of January 2022. This is equivalent to around 5.4% of the total population. In the United States, 623,405 persons have metastatic breast, prostate, lung, colorectal, bladder, or melanoma, and by the year 2025, that number is projected to rise to 693,452. Moreover, as per the data by Cancer Research UK, it is anticipated that there will be 28 million new cancer cases globally each year by 2040 if incidence remains steady and population growth and ageing continue at current rates. This is a 54.9% increase over 2020, and it is predicted to be larger in males (60.6% increase) than in women (48.8% increase). Thus, the aforementioned facts drive the market growth during the forecast period.

Patient Derived Xenograft (PDX) Model Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Patient Derived Xenograft (PDX) Model market is estimated to grow annually at a CAGR of around 13.2% over the forecast period (2023-2030)
  • Patient Derived Xenograft (PDX) Model industry is projected to grow at a significant rate owing to the growing prevalence of cancer.
  • Based on the tumor type, the breast cancer segment is expected to dominate the market over the forecast period.
  • Based on region, North America is expected to dominate the market over the forecast period.

Patient Derived Xenograft (PDX) Model Market- Segmentation Analysis:

  • The Global Patient Derived Xenograft (PDX) Model Market is segmented based on tumor type, model, end user and Region.
  • Based on the tumor type, the global Patient Derived Xenograft (PDX) Model market is segmented into prostate cancer, pancreatic cancer, lung cancer, breast cancer and others. The breast cancer segment is expected to dominate the market during the forecast period. Breast cancer still ranks as the leading cause of death for women worldwide, despite major improvements in detection and treatment methods over time. With current medicines, it is challenging to destroy tumors since they are made up of populations that are extremely varied, including those of breast cancer. Due to the inter-tumor heterogeneity of breast cancer, it is also difficult to accurately predict therapeutic efficacy using commonly used cancer models, such as cell lines created in vitro and in vivo. As a result, PDX models have been created to more realistically depict the variability of the origins of human malignancies. These models are expected to improve breast cancer therapy modalities. Thereby, driving the segment growth over the forecast period.

Patient Derived Xenograft (PDX) Model Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period due to the increasing prevalence of cancer. Moreover, the increasing R&D investments are also an important factor that propels the industry expansion. Furthermore, the presence of key players in the region is expected to propel the market growth. For instance, in April 2023, at the 2023 American Association for Cancer Research (AACR) Annual Meeting, Vincerx Pharma, Inc., a biopharmaceutical company aiming to address the unmet medical needs of cancer patients through paradigm-shifting therapeutics, presented a poster of preclinical data of VIP236 monotherapy treatment in PDX and metastatic PDX mouse models across various tumor types. Thus, this kind of initiative is expected to drive market growth in the region.

Patient Derived Xenograft (PDX) Model Market- Competitive Landscape:

The key players operating in the market are: WuXi AppTec, XenTech, Crown Bioscience, Altogen Labs, Envigo, Charles River Laboratories, Oncodesign, Hera Biolabs, The Jackson Laboratory and Abnova Corp.

Recent Developments:

In July 2022, GemPharmatech (GemPharmatech Co., Ltd.) announced that it has entered into a strategic license agreement with Charles River Laboratories, Inc. for the exclusive distribution of its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. The goal of this agreement is to speed up the development of novel therapeutics for a variety of unmet medical needs, particularly in immuno-oncology. To produce models that will be sold starting in 2023, Charles River will create foundation colonies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET KEY PLAYERS

  • WuXi AppTec
  • XenTech
  • Crown Bioscience
  • Altogen Labs
  • Envigo
  • Charles River Laboratories
  • Oncodesign
  • Hera Biolabs
  • The Jackson Laboratory
  • Abnova Corp.

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE

  • Prostate Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • Breast Cancer
  • Others

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET, BY MODEL

  • Mice
  • Rats

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER

  • Pharmaceutical And Biopharmaceutical Companies
  • Academic & Research Institutes
  • CROs & CDMOs

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Patient Derived Xenograft (PDX) Model Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Patient Derived Xenograft (PDX) Model Market Snippet by Tumor Type
    • 2.1.2. Patient Derived Xenograft (PDX) Model Market Snippet by Model
    • 2.1.3. Patient Derived Xenograft (PDX) Model Market Snippet by End User
    • 2.1.4. Patient Derived Xenograft (PDX) Model Market Snippet by Country
    • 2.1.5. Patient Derived Xenograft (PDX) Model Market Snippet by Region
  • 2.2. Competitive Insights

3. Patient Derived Xenograft (PDX) Model Key Market Trends

  • 3.1. Patient Derived Xenograft (PDX) Model Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Patient Derived Xenograft (PDX) Model Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Patient Derived Xenograft (PDX) Model Market Opportunities
  • 3.4. Patient Derived Xenograft (PDX) Model Market Future Trends

4. Patient Derived Xenograft (PDX) Model Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Patient Derived Xenograft (PDX) Model Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Patient Derived Xenograft (PDX) Model Market Landscape

  • 6.1. Patient Derived Xenograft (PDX) Model Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Patient Derived Xenograft (PDX) Model Market - By Tumor Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Tumor Type, 2022 & 2030 (%)
    • 7.1.2. Prostate Cancer
    • 7.1.3. Pancreatic Cancer
    • 7.1.4. Lung Cancer
    • 7.1.5. Breast Cancer
    • 7.1.6. Others

8. Patient Derived Xenograft (PDX) Model Market - By Model

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Model, 2022 & 2030 (%)
    • 8.1.2. Mice
    • 8.1.3. Rats

9. Patient Derived Xenograft (PDX) Model Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2022 & 2030 (%)
    • 9.1.2. Pharmaceutical And Biopharmaceutical Companies
    • 9.1.3. Academic & Research Institutes
    • 9.1.4. CROs & CDMOs

10. Patient Derived Xenograft (PDX) Model Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Patient Derived Xenograft (PDX) Model Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. WuXi AppTec
    • 11.2.2. XenTech
    • 11.2.3. Crown Bioscience
    • 11.2.4. Altogen Labs
    • 11.2.5. Envigo
    • 11.2.6. Charles River Laboratories
    • 11.2.7. Oncodesign
    • 11.2.8. Hera Biolabs
    • 11.2.9. The Jackson Laboratory
    • 11.2.10. Abnova Corp.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Patient Derived Xenograft (PDX) Model Market: Tumor Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Tumor Type
  • TABLE Global Patient Derived Xenograft (PDX) Model Market, by Tumor Type 2018-2030 (USD Million)
  • TABLE Patient Derived Xenograft (PDX) Model Market: Model Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Model
  • TABLE Global Patient Derived Xenograft (PDX) Model Market, by Model 2018-2030 (USD Million)
  • TABLE Patient Derived Xenograft (PDX) Model Market: End User Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by End User
  • TABLE Global Patient Derived Xenograft (PDX) Model Market, by End User 2018-2030 (USD Million)
  • TABLE Patient Derived Xenograft (PDX) Model Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Patient Derived Xenograft (PDX) Model Market, by Region 2018-2030 (USD Million)
  • TABLE North America Patient Derived Xenograft (PDX) Model Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Patient Derived Xenograft (PDX) Model Market, by Tumor Type, 2018-2030 (USD Million)
  • TABLE North America Patient Derived Xenograft (PDX) Model Market, by Model, 2018-2030 (USD Million)
  • TABLE North America Patient Derived Xenograft (PDX) Model Market, by End User, 2018-2030 (USD Million)
  • TABLE Europe Patient Derived Xenograft (PDX) Model Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Patient Derived Xenograft (PDX) Model Market, by Tumor Type, 2018-2030 (USD Million)
  • TABLE Europe Patient Derived Xenograft (PDX) Model Market, by Model, 2018-2030 (USD Million)
  • TABLE Europe Patient Derived Xenograft (PDX) Model Market, by End User, 2018-2030 (USD Million)
  • TABLE Asia Pacific Patient Derived Xenograft (PDX) Model Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Patient Derived Xenograft (PDX) Model Market, by Tumor Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Patient Derived Xenograft (PDX) Model Market, by Model, 2018-2030 (USD Million)
  • TABLE Asia Pacific Patient Derived Xenograft (PDX) Model Market, by End User, 2018-2030 (USD Million)
  • TABLE Latin America Patient Derived Xenograft (PDX) Model Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Patient Derived Xenograft (PDX) Model Market, by Tumor Type, 2018-2030 (USD Million)
  • TABLE Latin America Patient Derived Xenograft (PDX) Model Market, by Model, 2018-2030 (USD Million)
  • TABLE Latin America Patient Derived Xenograft (PDX) Model Market, by End User, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Patient Derived Xenograft (PDX) Model Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Patient Derived Xenograft (PDX) Model Market, by Tumor Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Patient Derived Xenograft (PDX) Model Market, by Model, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Patient Derived Xenograft (PDX) Model Market, by End User, 2018-2030 (USD Million)

List of Figures

  • FIGURE Patient Derived Xenograft (PDX) Model Market Segmentation
  • FIGURE Market research Modelology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Tumor Type segment market share analysis, 2022 & 2030
  • FIGURE Tumor Type segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Model segment market share analysis, 2022 & 2030
  • FIGURE Model segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE End User segment market share analysis, 2022 & 2030
  • FIGURE End User segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Patient Derived Xenograft (PDX) Model Market share and leading players, 2022
  • FIGURE Europe Patient Derived Xenograft (PDX) Model Market share and leading players, 2022
  • FIGURE Asia Pacific Patient Derived Xenograft (PDX) Model Market share and leading players, 2022
  • FIGURE Latin America Patient Derived Xenograft (PDX) Model Market share and leading players, 2022
  • FIGURE Middle East and Africa Patient Derived Xenograft (PDX) Model Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Patient Derived Xenograft (PDX) Model Market share analysis by country, 2022
  • FIGURE Germany Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Patient Derived Xenograft (PDX) Model Market share analysis by country, 2022
  • FIGURE India Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Patient Derived Xenograft (PDX) Model Market share analysis by country, 2022
  • FIGURE Brazil Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Patient Derived Xenograft (PDX) Model Market share analysis by country, 2022
  • FIGURE Saudi Arabia Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Patient Derived Xenograft (PDX) Model Market size, forecast and trend analysis, 2018 to 2030 (USD Million)